Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mucinous adenocarcinoma of the appendix is a very rare, slow growing, well-differentiated epithelial neoplasm of the appendix characterized by abundant mucin production. Clinically, it presents as acute appendicitis (with abdominal pain, fever, leukocytosis) or as pseudomyxoma peritonei (wide-spread presence of mucin within the peritoneal cavity), however some patients may be completely asymptomatic at the time of diagnosis. In many cases, a second gastrointestinal malignancy is present.
Biomarker and diagnostic research for mucinous adenocarcinoma of the appendix has been reported in the published literature.
2 clinical trials registered. Interventions under study include other interventions, gene therapy, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
113 publications have been identified in PubMed for mucinous adenocarcinoma of the appendix. Research spans Case Report / Case Series (41%), Epidemiology / Natural History (20%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 46 |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 9:45 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
41%
Disease patterns and progression | 23 | 20% |
Research summaries | 22 | 19% |
Laboratory research | 8 | 7% |
Other research | 5 | 4% |
Testing and diagnosis research | 4 | 4% |
Clinical study results | 4 | 4% |
New treatment approaches | 1 | 1% |
Kok SY (2026). [PMID: 42146324](https://pubmed.ncbi.nlm.nih.gov/42146324/). *J Surg Case Rep*. [Case Report / Case Series]
Lin V (2026). [PMID: 41727240](https://pubmed.ncbi.nlm.nih.gov/41727240/). *Journal of surgical case reports*. [Case Report / Case Series]
Yue B (2026). [PMID: 41885734](https://pubmed.ncbi.nlm.nih.gov/41885734/). *Int J Surg Pathol*. [Case Report / Case Series]
Ailioaie RC (2026). [PMID: 42122958](https://pubmed.ncbi.nlm.nih.gov/42122958/). *J Clin Med*. [Diagnostic / Biomarker]
Qian DM (2026). [PMID: 41657806](https://pubmed.ncbi.nlm.nih.gov/41657806/). *Am J Cancer Res*. [Case Report / Case Series]
Gowda T (2026). [PMID: 41721166](https://pubmed.ncbi.nlm.nih.gov/41721166/). *Annals of surgical oncology*. [Epidemiology / Natural History]
Garcia Ramírez MH (2026). [PMID: 42089047](https://pubmed.ncbi.nlm.nih.gov/42089047/). *Cureus*. [Case Report / Case Series]
Baron E (2026). [PMID: 41317532](https://pubmed.ncbi.nlm.nih.gov/41317532/). *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. [Epidemiology / Natural History]
Bianco G (2026). [PMID: 41650662](https://pubmed.ncbi.nlm.nih.gov/41650662/). *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. [Review / Meta-Analysis]
Baranova K (2026). [PMID: 41984223](https://pubmed.ncbi.nlm.nih.gov/41984223/). *Virchows Arch*. [Review / Meta-Analysis]